Cargando…
Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
Median arcuate ligament syndrome (MALS) is a rare constellation of neurogenic gastrointestinal (GI) symptoms resulting from compression of the celiac trunk and celiac plexus by the median arcuate ligament. MALS is characterized by nonspecific symptoms including nausea, vomiting, diarrhea, bloating,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333558/ https://www.ncbi.nlm.nih.gov/pubmed/35911332 http://dx.doi.org/10.7759/cureus.26401 |
_version_ | 1784758904146624512 |
---|---|
author | Kharbat, Abdurrahman F Kile, Ranger Kankam, Alfred Galvan, Bernardo Holder, Katherine G Soliman, Basem |
author_facet | Kharbat, Abdurrahman F Kile, Ranger Kankam, Alfred Galvan, Bernardo Holder, Katherine G Soliman, Basem |
author_sort | Kharbat, Abdurrahman F |
collection | PubMed |
description | Median arcuate ligament syndrome (MALS) is a rare constellation of neurogenic gastrointestinal (GI) symptoms resulting from compression of the celiac trunk and celiac plexus by the median arcuate ligament. MALS is characterized by nonspecific symptoms including nausea, vomiting, diarrhea, bloating, unintentional weight loss due to food aversion, and postprandial epigastric abdominal pain. We present a case of atypical, chronic MALS that confounded clinicians for over a decade and led to various misdiagnoses, including early-onset Parkinson’s disease. Of the constellation of symptoms that MALS may present with, postprandial epigastric pain is a classic symptom and increases the index of suspicion for the diagnosis; however, the absence of the classic symptom of postprandial epigastric pain and the predomination of nonspecific GI symptoms and syncope in our patient further clouded clinicians’ ability to diagnose MALS. Upon further investigation, we elucidated a link between gabapentin, which our patient was chronically prescribed, and its efficacy in decreasing neurogenic hypersensitivity in the GI tract. Our case and the implications of gabapentin use to decrease neurogenic pain from MALS represents a novel addition to the literature on MALS treatment modalities and elucidates new avenues for continued research in the use of gabapentin as a symptom-modifying agent in the nonoperative and preoperative treatment of MALS. |
format | Online Article Text |
id | pubmed-9333558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-93335582022-07-30 Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities Kharbat, Abdurrahman F Kile, Ranger Kankam, Alfred Galvan, Bernardo Holder, Katherine G Soliman, Basem Cureus Pain Management Median arcuate ligament syndrome (MALS) is a rare constellation of neurogenic gastrointestinal (GI) symptoms resulting from compression of the celiac trunk and celiac plexus by the median arcuate ligament. MALS is characterized by nonspecific symptoms including nausea, vomiting, diarrhea, bloating, unintentional weight loss due to food aversion, and postprandial epigastric abdominal pain. We present a case of atypical, chronic MALS that confounded clinicians for over a decade and led to various misdiagnoses, including early-onset Parkinson’s disease. Of the constellation of symptoms that MALS may present with, postprandial epigastric pain is a classic symptom and increases the index of suspicion for the diagnosis; however, the absence of the classic symptom of postprandial epigastric pain and the predomination of nonspecific GI symptoms and syncope in our patient further clouded clinicians’ ability to diagnose MALS. Upon further investigation, we elucidated a link between gabapentin, which our patient was chronically prescribed, and its efficacy in decreasing neurogenic hypersensitivity in the GI tract. Our case and the implications of gabapentin use to decrease neurogenic pain from MALS represents a novel addition to the literature on MALS treatment modalities and elucidates new avenues for continued research in the use of gabapentin as a symptom-modifying agent in the nonoperative and preoperative treatment of MALS. Cureus 2022-06-28 /pmc/articles/PMC9333558/ /pubmed/35911332 http://dx.doi.org/10.7759/cureus.26401 Text en Copyright © 2022, Kharbat et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pain Management Kharbat, Abdurrahman F Kile, Ranger Kankam, Alfred Galvan, Bernardo Holder, Katherine G Soliman, Basem Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities |
title | Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities |
title_full | Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities |
title_fullStr | Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities |
title_full_unstemmed | Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities |
title_short | Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities |
title_sort | gabapentin as a symptomatic modifier in median arcuate ligament syndrome: a case report and assessment of treatment modalities |
topic | Pain Management |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333558/ https://www.ncbi.nlm.nih.gov/pubmed/35911332 http://dx.doi.org/10.7759/cureus.26401 |
work_keys_str_mv | AT kharbatabdurrahmanf gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities AT kileranger gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities AT kankamalfred gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities AT galvanbernardo gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities AT holderkatherineg gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities AT solimanbasem gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities |